Eric Furfine
Eric brings experience in leadership roles in biotechnology and pharmaceutical companies to the role of Chief Executive and Scientific Office at Mosaic.
He is a visionary leader and drug hunter in the biotech and pharmaceutical industry. As CSO and President of R&D at Eleven Biotherapeutics, his leadership drove an IPO that financed Phase 3 clinical studies and a lucrative licensing deal on a second therapeutic asset. His building the Adnectin protein therapeutic discovery platform at Adnexus resulted in the acquisition of the company by BMS, where subsequently five adnectins were advanced into clinical studies. As VP Preclinical Development at Regeneron, he played pivotal roles in developing game-changing drugs, such as Eylea.
Eric received his PhD in Biochemistry from Brandeis University